SCHEMBL4718686

SCHEMBL4718686

Cc1cccc(-c2cc(Nc3cccc4cnccc34)ncn2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
KDM4E B2RXH2 5/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPT P10636 5/20 0.47
KMT2A Q03164 4/20 0.47
FAAH O00519 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
KDR P35968 3/20 0.43
CCR4 P51679 1/20 0.43
TRPV1 Q8NER1 2/20 0.43
MEN1 O00255 2/20 0.42
KARS1 Q15046 1/20 0.41
PDE4B Q07343 1/20 0.41
KMO O15229 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716052 0.88 PDE4B (0.51) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL4715734 0.86 TRPV1 (0.45) ALDH1A1KDM4EMAPTKMT2ACCR4
SCHEMBL4718692 0.86 TRPV1 (0.49) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL4718526 0.86 TRPV1 (0.41) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL4719637 0.85 TRPV1 (0.48) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL4720736 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTKMT2ASMN1; SMN2
SCHEMBL4718454 0.84 MAPK1 (0.45) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL4715943 0.84 TRPV1 (0.55) FAAHTRPV1KMO
SCHEMBL4718622 0.84 PDE4B (0.41) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL4716401 0.83 TRPV1 (0.48) ALDH1A1KDM4EHPGDMAPTFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ALDH1A1 2473/4885KDM4E 4502/4885CYP1A2 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.